Comprehensive pulmonary rehabilitation according to severity of COPD  by Takigawa, Nagio et al.
ARTICLE IN PRESSRespiratory Medicine (2007) 101, 326–3320954-6111/$ - s
doi:10.1016/j.r
Correspond
Japan. Tel.: +8
E-mail addrComprehensive pulmonary rehabilitation according
to severity of COPD
Nagio Takigawaa,b,, Atsuhiko Tadaa, Ryo Sodaa, Syuji Takahashia,
Noriko Kawataa, Takuo Shibayamaa, Hiroshi Matsumotoa,
Noboru Hamadaa, Atsushi Hiranoa, Goro Kimuraa, Chiharu Okadaa,
Shigeto Endoc, Motohiro Yamashitac, Hiroshi Dated, Kiyoshi TakahashiaaDepartment of Internal Medicine, National Hospital Organization, Minami-Okayama Medical Center,
4066 Hayashima, Okayama 701-0304, Japan
bDepartment of Respiratory Medicine, Okayama University Hospital, 2-5-1 Shikata-cho,
Okayama 700-8558, Japan
cSurgery, National Hospital Organization, Minami-Okayama Medical Center, 4066 Hayashima,
Okayama 701-0304, Japan
dThoracic Surgery, Okayama University Hospital, 2-5-1 Shikata-cho, Okayama 700-8558, Japan
Received 30 August 2005; accepted 28 March 2006KEYWORDS
Pulmonary rehabili-
tation;
COPD;
Classiﬁcation of se-
verity;
Pulmonary function;
6-min walk testee front matter & 2006
med.2006.03.044
ing author. Department
1 86 235 7227; fax: +81 8
ess: ntakigaw@md.okaySummary A new classiﬁcation for the severity of COPD was proposed at GOLD
2003: stage I: FEV1X80% predicted; stage II: 50%pFEV1o80%; stage III: 30%p
FEV1o50%; and stage IV: FEV1o30%. To elucidate the acute effects of pulmonary
rehabilitation (PR) on patients with different stages of COPD, data on pulmonary
function, arterial blood gas analysis, the 6-min walk test, respiratory muscle
strength, and activities of daily living were analyzed before and after our
comprehensive 4- to 8-week inpatient PR program between 1992 and 2003. A total
of 225 patients (201 men and 24 women; 21 with stage II, 79 with stage III, and 125
with stage IV COPD) was assessed. There were signiﬁcant differences in FEV1%
predicted and % residual volume in stages III and IV, in % vital capacity in stages II, III
and IV, and in % total lung capacity in stage II when comparing the changes between
pre- and post-PR. Signiﬁcant differences of PaO2 in stages III and IV and PaCO2 in
stage IV were found when comparing the changes between pre- and post-PR. The 6-
min walk distance was signiﬁcantly increased after PR by an average of
approximately 50m for all staged patients. Respiratory muscle strength was also
signiﬁcantly increased in stages III and IV. Activities of daily living were signiﬁcantly
improved in all stages. These results showed that patients with COPD had beneﬁtedElsevier Ltd. All rights reserved.
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Pulmonary rehabilitation for COPD 327from PR regardless of disease severity. The effects included improvement in
pulmonary function, arterial blood gas analysis, 6-min walk distance, respiratory
muscle strength, and activities of daily living although there were some differences
among the three stages.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Pulmonary rehabilitation (PR) is an effective inter-
vention in patients with COPD.1,2 Berry et al.3
reported that all patients with COPD beneﬁted
from PR, regardless of the severity of the disease.
They deﬁned disease severity according to the 1995
American Thoracic Society (ATS) scale.4 Using the
1-s forced expiratory volume (FEV1), severity was
classiﬁed into three stages: stage I: FEV1X50%
predicted; stage II: 35%pFEV1o50%; and stage III:
FEV1o35%. A new classiﬁcation of severity was
proposed in the GOLD 2003 guideline.5 The new
guideline deﬁnes 5 stages: stage 0: normal spiro-
metry with chronic symptoms; stage I: FEV1X80%
predicted; stage II: 50%pFEV1o80%; stage III:
30%pFEV1o50%; and stage IV: FEV1o30%. Stages
I, II and III of the 1995 ATS classiﬁcation approxi-
mately correspond to stages II, III, and IV of the
GOLD 2003 classiﬁcation, respectively, in terms of
the values of FEV1 predicted.
2 PR was recom-
mended from stage II (FEV1o80%) COPD patients.5
To the best of our knowledge, there have been no
reports that describe the effect of comprehensive
PR on COPD on the basis of the new staging. To
elucidate the beneﬁt of PR for patients with new
stages II, III, and IV COPD, we analyzed data on
pulmonary function, arterial blood gas analysis, the
6-min walk test, respiratory muscle strength, and
activities of daily living (ADL) before and after our
inpatient PR program.Methods
The diagnosis of COPD and the classiﬁcation of
severity were deﬁned according to the global
strategy for the diagnosis, management, and
prevention of COPD updated in 2004.6 The patients
had symptoms of cough, sputum, or dyspnea, and/
or a history of exposure to risk factors for the
disease. The presence of a post-bronchodilator
FEV1o80% of the predicted value in combination
with an FEV1/forced vital capacity (FVC)o70%
conﬁrms the presence of airﬂow limitation that is
not fully reversible. Reversibility was deﬁned as an
increase in FEV1 greater than 12% and/or 200mLafter inhalation of b-agonist. The classiﬁcation of
severity was as follows: moderate COPD (stage II),
50%pFEV1o80% predicted; severe COPD (stage III),
30%pFEV1o50%; and very severe COPD (stage IV),
FEV1o30%. The inclusion criteria for this study
were: (1) stage II, III or IV COPD, (2) the ability to
walk for 6min, (3) never having participated in a
rehabilitation program before, and (4) the absence
of a comorbid disease that would preclude the
patient from participating in a rehabilitation
program. The patients received optimal medical
treatment including b-agonists, anticholinergic
drugs, theophylline, and/or (inhaled or oral)
steroids. A stable condition whilst receiving med-
ical treatment was required before PR commenced.
Baseline data recorded before PR consisted of
height, body weight, body mass index (BMI), serum
total protein and albumin levels, smoking status,
and the use of supplemental oxygen at home.
Pulmonary function data such as FEV1, FEV1%
predicted, FEV1/FVC, vital capacity (VC), %VC, %
total lung capacity (TLC), and % residual volume
(RV) were assessed by spirometry and lung volume
testing with helium dilution (Chestac-25, Chest,
Tokyo, Japan). Predicted FEV1 values were ob-
tained from the Japanese Respiratory Society
guideline7: FEV1 (L) for men ¼ 0.036 height
(cm)0.028 age (yr)1.178; FEV1 (L) for wo-
men ¼ 0.022 height (cm)0.022 age (yr)
0.055. Arterial blood gases were taken at rest.
Patients with hypoxemia at rest (o55 Torr) were
prescribed oxygen therapy, meaning that PaO2 and
PaCO2 were measured while they were receiving
oxygen. The maximal inspiratory (PImax) and ex-
piratory (PEmax) mouth pressures were measured
using a respiratory muscle dynamometer (Vital
power KH-101 Chest, Tokyo, Japan). The patients
performed 6-min walk (6 MW) tests. The 6-min walk
distance (6 MWD) was deﬁned as the longest
distance possible without encouragement. Subjects
were allowed to stop and rest if necessary. The ﬁrst
6 MWD without a training session was accepted.
The subjects walked with hemoglobin oxygen
saturation (SpO2) monitors. DSpO2 (SpO2 level just
before 6 MW—minimum SpO2 level during 6 MW)
was also assessed. ADL was assessed using ques-
tionnaires based on velocity of motion and short-
ness of breath in daily activity with various grades
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defecation, face washing, brushing teeth, bathing,
dressing, walking in a room, walking in wards,
walking in the hospital, walking up the stairs, and
shopping (Table 1).8,9 A perfect score of the two
parameters is 30 points each and higher scores
mean greater daily activity. These baseline mea-
surements were made during the week before and
after PR.
Comprehensive PR was performed using a 4- to
8-week hospital-based program. Patients attended
the rehabilitation unit on 5 half-days per week.
Exercise included cycle ergometer training (5min),
treadmill training (5min), upper and lower extremity
strength training (5–10min), breathing therapies
(5–20min), and relaxation therapies (10–20min) for
total 30–60min. Patients underwent both cycle ergo-
meter and treadmill training. The exercise strength
of the training was based on tolerance determined by
symptomatic and physiologic criteria resulting from
exercise tests. Pulse oximetry was used to supervise
patients during exercise. If the SpO2 fell below 90%,
oxygen supplementation was provided to maintain an
SpO2X90%. During exercise, the target pulse rate
was determined by the formula: (138—Age 0.5).10
If the patients or physical therapists considered the
workload to be low or if the patients did not reach
their target pulse rate, the physical therapists
increased workload by steps of 25% until the workload
was appropriate or until the target pulse rate was
reached. If patients could not tolerate the workload
because of dyspnea or leg fatigue, or if the pulse rate
was more than 10/min above the target pulse rate,Table 1 Assessment of ADL.
Velocity of
motion
Shortness of
breath
Eating 0, 1, 2, or 3 0, 1, 2, or 3
Defecation 0, 1, 2, or 3 0, 1, 2, or 3
Face washing and
brushing teeth
0, 1, 2, or 3 0, 1, 2, or 3
Bathing 0, 1, 2, or 3 0, 1, 2, or 3
Dressing 0, 1, 2, or 3 0, 1, 2, or 3
Walking in a room 0, 1, 2, or 3 0, 1, 2, or 3
Walking in wards 0, 1, 2, or 3 0, 1, 2, or 3
Walking in the
hospital
0, 1, 2, or 3 0, 1, 2, or 3
Walking up the stairs 0, 1, 2, or 3 0, 1, 2, or 3
Shopping 0, 1, 2, or 3 0, 1, 2, or 3
Total /30 /30
Scores for velocity of motion are 0: impossible or almost
impossible; 1: impossible without rest; 2: possible but
slow; 3: possible with ease. Scores of shortness of breath
are 0: intolerable; 1: hard; 2: easy; 3: no shortness of
breath.the physical therapists allowed the patient to rest
and decreased the workload by 25%.
Educational activities included an understanding
of pulmonary pathophysiology, the mechanisms of
breathlessness, the importance of exercise and
nutritional support, pulmonary medications, how to
deal with breathlessness and exacerbations, how to
clear sputum, how to apply the lessons of rehabi-
litation to daily life, the usefulness of oxygen
therapy, the indications for lung volume reduction
surgery (LVRS), and the importance of smoking
cessation. Twelve educational sessions per month
were delivered by seven doctors, three specialist
respiratory nurses, a physical therapist and a
dietician, and educational videos were shown
instead of lectures on the other days. This educa-
tion program was 30min long on weekdays and was
repeated every month.
Statistical analyses were performed using the
SPSS Base System
TM
and Advanced Statistics
TM
programs (SPSS, Chicago, IL, USA). To compare
categorized variables between different stage
groups, the Mann-Whitney U test was used. Non-
parametric paired variables between before and
after PR were analyzed with the Wilcoxon test.Results
Between July 1992 and June 2003, 201 men and 24
women who participated in our PR program (for a
median period of 5 weeks) were assessed in this
study. The patient characteristics of the 225
patients (21 at stage II, 79 at stage III, and 125 at
stage IV) are shown in Table 2. The median age of
all the patients was 69 yr (range 45–84 yr). The
younger patients were categorized in the more
severe stages and there were signiﬁcant differ-
ences in ages between each stage (P ¼ 0.028 for
stage II and III, P ¼ 0.002 for stage III and IV).
Measures of nutritional status such as BMI, total
protein and albumin levels, and smoking index were
not signiﬁcantly different among the three groups.
Home oxygen therapy was administrated to pa-
tients with more advanced COPD.
Pulmonary function data on pre-PR and post-PR
by stage are shown in Table 3. Before PR, FEV1,
FEV1% predicted, FEV1/FVC, and %VC were de-
creased to a greater extent in the more advanced
stages: all P values are 0.000 between stage II and
III or between stage III and IV. The difference in VC
between stage II and III was not signiﬁcant
(P ¼ 0.083), but was signiﬁcant (P ¼ 0.000)
between stage III and IV. Although there were no
differences in %TLC among the three stages, %RV
ARTICLE IN PRESS
Table 2 Patient characteristics.
Stages
II (n ¼ 21) III (n ¼ 79) IV (n ¼ 125)
Sex (men/women) 15/6 68/11 118/7
Age (median yr, range) 72 (63–81) 69 (54–84) 67 (45–79)
Height (cm) 158.377.5 160.676.4 162.376.6
Weight (kg) 48.279.0 50.179.3 48.879.1
Body mass index (kg/m2) 19.172.6 19.373.1 18.573.2
Total protein (g/dL) 6.870.6 6.770.6 6.570.5
Albumin (g/dL) 3.870.4 3.970.4 3.970.4
Smoker/never-smoker 21/0 77/2 121/4
Smoking index 10197499 11027667 11607675
Oxygen therapy (yes/no) 3/18 25/54 75/50
Values for height, weight, total protein, albumin, and smoking index ( ¼ cigarettes/day year) are means7standard deviation.
Table 3 Pulmonary function data: pre- and post-
pulmonary rehabilitation (PR) by stage.
Parameters Stages
II III IV
FEV1 (L)
Pre-PR 1.4070.30 0.9770.23 0.6370.13
Post-PR 1.4370.32 1.0670.36 0.7570.21
P 0.268 0.015 0.000
FEV1 (% predicted)
Pre-PR 60.277.0 37.576.2 22.774.5
Post-PR 62.079.2 40.4711.3 27.177.3
P 0.212 0.014 0.000
FEV1/FVC (%)
Pre-PR 55.878.6 45.778.6 39.879.6
Post-PR 52.976.6 47.0711.7 39.179.7
P 0.126 0.470 0.159
VC (L)
Pre-PR 2.8070.67 2.5170.64 1.9870.58
Post-PR 2.9770.70 2.6970.72 2.2770.58
P 0.009 0.010 0.000
%VC (%)
Pre-PR 96.0714.7 80.5715.4 61.0716.6
Post-PR 103.4717.6 85.6718.3 69.9716.1
P 0.019 0.012 0.000
%TLC (%)
Pre-PR 127.8711.2 138.8739.7 137.6776.3
Post-PR 133.1715.1 127.1720.3 128.9721.3
P 0.123 0.023 0.565
%RV (%)
Pre-PR 197.7734.0 246.17122.5 265.97127.8
Post-PR 194.4735.0 199.3764.3 214.4752.6
P 0.575 0.003 0.003
Values are means7standard deviation.
Pulmonary rehabilitation for COPD 329increased from stages II to IV (P ¼ 0.008). There
were signiﬁcant differences of FEV1, FEV1% pre-
dicted and %RV in stages III and IV, VC and %VC inthree stages, and of %TLC in stage II when
comparing the changes between pre- and post-PR.
Arterial blood gas data are shown in Table 4.
Signiﬁcant differences in pH were found among the
three stages before PR (stage II versus stage III:
P ¼ 0.010; stage III versus stage IV: P ¼ 0.000).
Although there were no differences in PaO2 among
three stages, PaCO2 was elevated in patients with
more advanced stage before PR (stage II versus
stage III: P ¼ 0.000; stage III versus stage IV:
P ¼ 0.000). Signiﬁcant differences of PaO2 in stages
III and IV and PaCO2 in stage IV and were found when
comparing the changes between pre- and post-PR.
The results of the 6 MW test are shown in Table 5.
Although there were no differences in distance or
DSpO2 between stages II and III, there were
signiﬁcant differences between stages III and IV
before PR (distance: P ¼ 0.000; DSpO2: P ¼ 0.003).
6 MWD in three stages was signiﬁcantly increased
after PR up to approximately 50m. DSpO2 was
signiﬁcantly increased (by an average of 1.4%) in
patients with stage IV. There were no differences in
respiratory muscle strength such as PEmax and PImax
in the three stages before PR and respiratory
muscle strength was signiﬁcantly improved in
stages III and IV (Table 6). There was no difference
in ADL between stages II and III, but a signiﬁcant
difference between stages III and IV before PR
(velocity of motion: P ¼ 0.000; shortness of breath:
P ¼ 0.000). The scores of both parameters im-
proved signiﬁcantly after PR in all stages (Table 7).Discussion
PR is an effective treatment for patients with COPD
in terms of exercise capacity and health-related
ARTICLE IN PRESS
Table 4 Arterial blood gas data: pre- and post-
pulmonary rehabilitation (PR) by stage.
Parameters Stages
II III IV
pH
Pre-PR 7.4570.04 7.4370.03 7.4170.03
Post-PR 7.4370.02 7.4370.03 7.4170.03
P 0.083 0.719 0.158
PaO2 (Torr)
Pre-PR 71.175.9 68.879.3 68.3710.9
Post-PR 72.179.6 71.679.4 70.6710.1
P 0.881 0.013 0.008
PaCO2 (Torr)
Pre-PR 36.473.4 40.474.9 47.378.6
Post-PR 37.473.9 40.074.4 45.777.0
P 0.204 0.461 0.014
Values are means7standard deviation.
Table 5 The 6-min walking test: pre- and post-
pulmonary rehabilitation (PR) by stage.
Parameters Stages
II III IV
Distance (m)
Pre-PR 340784 341781 289795
Post-PR 388759 388778 341779
P 0.015 0.000 0.000
DSpO2 (%)
Pre-PR 6.976.9 6.074.6 8.275.5
Post-PR 5.073.4 7.074.5 9.675.6
P 0.819 0.100 0.007
Values are means7standard deviation.
Table 6 Respiratory muscle strength: pre- and
post-pulmonary rehabilitation (PR) by stage.
Parameters Stages
II III IV
PEmax (cmH2O)
Pre-PR 48.3719.0 55.8721.5 63.8725.6
Post-PR 68.1730.6 72.5730.1 72.3728.4
P 0.051 0.000 0.007
PImax (cmH2O)
Pre-PR 43.6721.6 41.8717.7 40.3719.2
Post-PR 54.1731.8 51.2723.8 50.7722.9
P 0.314 0.001 0.000
Values are means7standard deviation.
Table 7 Activities of daily living scores: pre- and
post-pulmonary rehabilitation (PR) by stage.
Parameters Stages
II III IV
Velocity of motion
Pre-PR 24.674.1 22.876.0 18.176.5
Post-PR 25.974.2 25.274.5 21.175.9
P 0.023 0.000 0.000
Shortness of breath
Pre-PR 21.376.1 20.076.0 15.776.1
Post-PR 24.474.4 23.174.9 18.875.7
P 0.001 0.000 0.000
Values are means7standard deviation.
N. Takigawa et al.330quality of life.1,2 GOLD 2004 recommended PR for
COPD patients from stage II (FEV1o80%).6 Compre-
hensive PR is thought to be most effective when
delivered as physiological training for 4–12 weeks,
with strength training, respiratory muscle training,
education, psychological and behavioral interven-
tion, physiotherapy, relaxation exercises, and
nutritional support.11 Our comprehensive 4- to 8-
week PR program was modeled on this concept.
Berry et al.3 showed that exercise training alone
improved physical function in patients at all stages.
The present study conﬁrmed that patients with an
FEV1o80% (stages II, III, and IV) made gains in
physical function with comprehensive PR. In the
present study, the number of patients in each stagewas very different: 21 in stage II, 79 in stage III, and
125 in stage IV. In Berry’s study, the group with mild
disease (corresponding to stage II in this study)
included a large number of patients (n ¼ 99) as
compared with the moderate (n ¼ 36) and severe
(n ¼ 16) groups.3 The distribution of patients
among the stages in our study was the opposite of
Berry’s study. Although an imbalance of patient
numbers may result in signiﬁcance at one stage and
non-signiﬁcance at another stage, Berry’s study and
our study showed a similar trend to improvement of
pulmonary function. VC and %VC were signiﬁcantly
increased in all stages after PR although they did
not mention about VC change. We do not have a
clear explanation as to why the VC improved. We
preliminary measured the expansion rate of thorax
at inspiration and expiration in some patients. The
ratio of expansion rates after and before PR was
correlated with the VC increase (data not shown).
This may be one of the reasons for the observed
improvement.
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after PR was 61.2, 72.7, and 34.2m in mild,
moderate, and severe disease, respectively. In the
present study, the average increase in 6 MWD after
PR was 48, 47, and 52m in stages II, III and IV,
respectively. Meta-analysis showed an average
increase of 55.7m in the 6MW test after PR,
although they did not refer to stages.1 The present
study showed that 6 MWD was increased by
approximately 50m for the all staged patients.
We acknowledge the need of a training session to
avoid a learning effect biasing the results. How-
ever, all the patients did not always undergo
the training session before PR. Of the 225 patients
in this study, 21 were classiﬁed as having
stage II COPD, 79 stage III, and 125 stage IV. The
patients with stages II and III COPD tended to
increase their 6 MWD to some extent after training
session (by a several meters, at most). Some of the
patients with stage IV were not willing to do the 6
MW test twice before PR because of breathlessness.
Some did not walk as fast as possible without
encouragement and their 6 MWD after training
session decreased. Accordingly, we did not carry
out a training session and accepted their ﬁrst 6
MWD to unify the condition. The 6 MWD in patients
in three stages of COPD was increased after PR up
to approximately 50m, which could not be ex-
plained by only the learning effect. However, we
acknowledge the limits caused to the absence of a
training session. In a future study, we should
evaluate the real gain of 6 MWD by carrying out a
training session. DSpO2 was signiﬁcantly increased
(by an average of 1.4%) in patients with stage IV. PR
improved the 6 MWD, but did not improve the
DSpO2. This result conﬁrmed that DSpO2 during
walking was not correlated with distance.12,13
Concerning respiratory muscle strength, Coppoolse
et al.14 reported that PImax increased after PR
although they did not refer to the severity of the
disease. Our results showed that PEmax and PImax
were both signiﬁcantly increased in stages III and IV.
LVRS is considered the optional treatment for
severe COPD6 and we have previously reported
that PR is the most important component of
preparation prior to LVRS.15 Improvement of re-
spiratory muscle strength may contribute to the
reduction of complications of LVRS. ADL were also
improved in all stages after PR, which means that
patients became more active with reduction of
breathlessness. However, this study has a limitation
about assessment of ADL. This ADL scale has not
been validated in the English literature. It is not
available internationally and is supported by only
one published paper8 although it is recommended
from the Japanese Respiratory Society.9 We shoulduse a better known and accepted scale in a further
study.
The present study conﬁrmed that patients with
COPD had beneﬁted from PR regardless of disease
severity. The effects included improvement in
pulmonary function, arterial blood gas analysis, 6
MWD, respiratory muscle strength, and ADL,
although there were some differences among the
three stages. GOLD 2003 deﬁned stage 0 (at risk) as
normal spirometry with chronic symptoms and
stage I (mild COPD) as FEV1/FVCo70% and
FEV1X80% predicted, in addition to stages II, III,
and IV.5 The usefulness of PR in stages 0 and I
remains unclear. Because only two patients with
stage I underwent PR during this study, we could
not evaluate its effectiveness in stage I. The Nippon
COPD Epidemiology study showed that the pre-
valence of airﬂow limitation (FEV1/FVCo70%) was
10.9% in 2343 subjects aged 40 yr and that the
severity of airﬂow limitation was: 56% stage I, 38%
stage II, 5% stage III, and 1% stage IV.16 Early
intervention with comprehensive PR for early
stages may be useful to increase patient aware-
ness, reduce symptoms, and delay disease progres-
sion, and the indications for PR should be clariﬁed.Acknowledgements
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